Keymed Biosciences (2162) Stock Overview
A biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2162 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Keymed Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$53.95 |
| 52 Week High | HK$80.00 |
| 52 Week Low | HK$27.05 |
| Beta | -0.052 |
| 1 Month Change | -10.83% |
| 3 Month Change | -26.85% |
| 1 Year Change | 56.15% |
| 3 Year Change | 12.63% |
| 5 Year Change | n/a |
| Change since IPO | -20.66% |
Recent News & Updates
Recent updates
Revenues Not Telling The Story For Keymed Biosciences Inc. (HKG:2162) After Shares Rise 28%
Jul 17
Keymed Biosciences Inc.'s (HKG:2162) CEO Looks Like They Deserve Their Pay Packet
Jun 19Is Keymed Biosciences (HKG:2162) Using Debt Sensibly?
May 12Market Participants Recognise Keymed Biosciences Inc.'s (HKG:2162) Revenues Pushing Shares 31% Higher
Apr 06Growth Investors: Industry Analysts Just Upgraded Their Keymed Biosciences Inc. (HKG:2162) Revenue Forecasts By 11%
Mar 31Keymed Biosciences Inc. (HKG:2162) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 28Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?
Oct 21There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump
May 13News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat
Apr 03Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 31A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)
Nov 13Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts
Sep 03Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher
Mar 21Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth
Jun 27Shareholder Returns
| 2162 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -6.5% | -5.2% | -1.7% |
| 1Y | 56.2% | 105.2% | 29.4% |
Return vs Industry: 2162 underperformed the Hong Kong Biotechs industry which returned 105.2% over the past year.
Return vs Market: 2162 exceeded the Hong Kong Market which returned 29.4% over the past year.
Price Volatility
| 2162 volatility | |
|---|---|
| 2162 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.3% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 2162 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2162's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 1,469 | Bo Chen | www.keymedbio.com |
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodularis, and respiratory related indications. The company is also developing CMG901, a Claudin 18.2 antibody drug conjugate in Phase III trial to treat gastric and solid tumors; CM326, a recombinant humanized monoclonal antibody in Phase II trial for the treatment of CRSwNP and asthma; CM313, a humanized monoclonal antibody that targets CD38 in Phase I/II clinical study to treat systemic lupus erythematosus, primary immune thrombocytopenia, and IgA nephropathy; and CM355, a CD20 x CD3 bispecific antibody in Phase I/II clinical trial for the treatment of lymphoma.
Keymed Biosciences Inc. Fundamentals Summary
| 2162 fundamental statistics | |
|---|---|
| Market cap | HK$16.07b |
| Earnings (TTM) | -HK$284.05m |
| Revenue (TTM) | HK$962.73m |
Is 2162 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2162 income statement (TTM) | |
|---|---|
| Revenue | CN¥872.19m |
| Cost of Revenue | CN¥41.94m |
| Gross Profit | CN¥830.25m |
| Other Expenses | CN¥1.09b |
| Earnings | -CN¥257.34m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 95.19% |
| Net Profit Margin | -29.50% |
| Debt/Equity Ratio | 26.5% |
How did 2162 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 16:03 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Keymed Biosciences Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Wangbin Zhou | China International Capital Corporation Limited |